Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, alrea...

Descripción completa

Detalles Bibliográficos
Autores principales: Cefalo, Chiara Maria Assunta, Cinti, Francesca, Moffa, Simona, Impronta, Flavia, Sorice, Gian Pio, Mezza, Teresa, Pontecorvi, Alfredo, Giaccari, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393994/
https://www.ncbi.nlm.nih.gov/pubmed/30819210
http://dx.doi.org/10.1186/s12933-019-0828-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393994/
https://www.ncbi.nlm.nih.gov/pubmed/30819210
http://dx.doi.org/10.1186/s12933-019-0828-y

Ejemplares similares